Warning: The NCBI web site requires JavaScript to function. more...
Menopausal hormone therapy after breast cancer.
Colditz GA.
Breast Cancer Res. 2005;7(4):168-70. Epub 2005 Jun 1.
Related citations
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT, Robert NJ.
Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.
Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.
Col NF, Kim JA, Chlebowski RT.
Breast Cancer Res. 2005;7(4):R535-40. Epub 2005 May 19.
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA.
Ann Oncol. 2007 Jan;18(1):45-51. Epub 2006 Oct 9.
Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.
J Natl Cancer Inst. 2006 Jan 18;98(2):110-5.
Breast cancer risk with postmenopausal hormonal treatment.
Collins JA, Blake JM, Crosignani PG.
Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Epub 2005 Sep 8. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
Cancer. 2008 Apr 1;112(7):1437-44.
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R, Hamilton A, Beith J.
Cochrane Database Syst Rev. 2008 Oct 8;(4):CD004562. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD004562.
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Pennery E.
Eur J Oncol Nurs. 2008 Jul;12(3):233-43. Epub 2008 Mar 26. Review.
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M, MacGrogan G, Brouste V, Mathoulin-Pelissier S, Durand M, Mauriac L.
Cancer. 2007 Jun 1;109(11):2197-204.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M.
Clin Ther. 2007 Aug;29(8):1535-47. Review.
[Hormone replacement therapy in menopausal women previously treated for breast cancer].
This P.
Presse Med. 1996 Feb 3;25(4):141-4. Review. French.
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R.
Lancet Oncol. 2006 Dec;7(12):991-6. Erratum in: Lancet Oncol. 2007 Jan;8(1):6.
Postmenopausal hormone therapy and breast cancer.
[No authors listed]
Prescrire Int. 2009 Apr;18(100):66-7.
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE.
Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12.
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Bell R, Lewis J.
Curr Med Res Opin. 2007 May;23(5):1045-51.
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
Biganzoli L, Licitra S, Claudino W, Pestrin M, Leo AD.
Eur J Cancer. 2007 Oct;43(15):2270-8. Epub 2007 Aug 14. Review.
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ, Dawson CK, Lawrence DH, Bliss JM.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD003370.
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Baum M.
Eur J Cancer. 2005 Aug;41(12):1667-77. Review.
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M; German Adjuvant Breast Cancer Group.
J Clin Oncol. 2005 Nov 1;23(31):7842-8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on